NCT05276375View on ClinicalTrials.gov

Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
DRUG

Bronchipret

Bronchipret syrup (3x 5,4 ml daily) until day 14

Trial Locations (1)

60596

Fraunhofer ITMP - early clinical development, Frankfurt

Sponsors

Collaborators (1)

Bionorica SE
All Listed Sponsors
collaborator

Bionorica SE

INDUSTRY

lead

Dr. Frank Behrens

OTHER